| Bioactivity | Qc1 is a reversible and noncompetitive threonine dehydrogenase (TDH) inhibitor. Qc1 can be used for the research of Metabolic disease[1][2]. | ||||||||||||
| Target | TDH | ||||||||||||
| Invitro | Qc1 (10 μM; 2~24 hours; ES cells) shows that a substantial fraction of the total LC3 protein is in the LC3-I (cytoplasmic) form. After 16 h of TDH inhibition, most LC3 is converted to the LC3-II (lipid-modified) form, indicative of increased autophagic activity[2].. Qc1 blocks the charging of tetrahydrofolate. Qc1 prevents threonine dehydrogenase from catabolizing threonine into acetyl-CoA and glycine[1][2]. | ||||||||||||
| Name | Qc1 | ||||||||||||
| CAS | 403718-45-6 | ||||||||||||
| Formula | C23H16F3N3O2S | ||||||||||||
| Molar Mass | 455.45 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Wang J, et al. Metabolic specialization of mouse embryonic stem cells. Cold Spring Harb Symp Quant Biol. 2011;76:183-193. [2]. Alexander PB, et al. Targeted killing of a mammalian cell based upon its specialized metabolic state. Proc Natl Acad Sci U S A. 2011;108(38):15828-15833. |